Eli Lilly & Co. (LLY) Announces CFO Resignation

On June 5, 2024, Eli Lilly & Co. (NYSE: LLY) announced that Anat Ashkenazi resigned as executive vice president and chief financial officer of the Company to pursue another career opportunity outside of the pharmaceutical industry. Effective July 15, 2024, Gordon Brooks, age 55, group vice president, controller and corporate strategy, of the Company, will assume the role of interim chief financial officer of the Company.

During his 29-year career with the Company, Mr. Brooks has held various leadership roles across the Company’s finance organization, including as senior vice president, chief procurement officer, from February 2019 to March 2024, prior to becoming the group vice president, controller and corporate strategy. Previous finance leadership roles held by Mr. Brooks include chief financial officer for Lilly U.S. Bio-Medicines, chief financial officer of manufacturing and quality, leader of the Company’s corporate finance investment banking group, and general auditor.

There are no arrangements or understandings between Mr. Brooks and any person pursuant to which Mr. Brooks was selected as an officer. There is no family relationship between Mr. Brooks and any director or executive officer of the Company, and Mr. Brooks is not a party to any transaction subject to Item 404(a) of Regulation S-K involving the Company or any of its subsidiaries.

You May Also Be Interested In

• Amplitude Therapeutics signs taRNA vaccine deal with Eli Lilly
• Ocean Power Technologies revises fiscal 2026 results after audit
• NexPoint Residential Trust (NXRT) Reiterated at Market Perform by Citizens Post Guidance Cut